1.1 This document provides guidance on the assessment of risks to product quality within and related to PAT processes in the pharmaceutical industry. It addresses those risks to product quality arising from, associated with, identified by, or modified by the implementation of PAT in pharmaceutical development and manufacturing for primary, secondary, and biotech sectors of the industry. It does not replace those assessments of risk currently undertaken by pharmaceutical companies, but is, rather, an additional component focused specifically upon the evaluation and design of PAT processes. See Guide E2500 and ICH Q8.

Product Details

Published:

11/01/2022

Number of Pages:

11

File Size:

1 file , 190 KB

Redline File Size:

2 files , 520 KB

Note:

This product is unavailable in Russia, Ukraine, Belarus